National Bank of Canada FI Raises Stock Position in Insulet Co. (NASDAQ:PODD)

National Bank of Canada FI grew its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 148.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 70,805 shares of the medical instruments supplier's stock after acquiring an additional 42,337 shares during the quarter. National Bank of Canada FI owned about 0.10% of Insulet worth $18,485,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. SBI Securities Co. Ltd. bought a new stake in Insulet during the 4th quarter valued at about $36,000. SRS Capital Advisors Inc. increased its position in shares of Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after acquiring an additional 56 shares in the last quarter. TD Private Client Wealth LLC increased its position in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock valued at $53,000 after acquiring an additional 56 shares in the last quarter. Friedenthal Financial purchased a new position in Insulet in the 4th quarter worth approximately $57,000. Finally, Assetmark Inc. lifted its position in Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after acquiring an additional 246 shares in the last quarter.

Insider Activity at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. This represents a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company's stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Remove Ads

Analyst Ratings Changes

Several research analysts have recently weighed in on PODD shares. Raymond James restated an "outperform" rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Citigroup boosted their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on Insulet from $280.00 to $330.00 and gave the company an "overweight" rating in a research note on Thursday, December 12th. TD Cowen upped their price objective on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, January 3rd. Finally, Stifel Nicolaus upped their price target on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $292.06.

Insulet Price Performance

Shares of Insulet stock traded down $4.50 during mid-day trading on Tuesday, reaching $251.73. 302,696 shares of the stock traded hands, compared to its average volume of 714,646. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The business has a 50-day moving average of $269.47 and a 200 day moving average of $259.99. The stock has a market capitalization of $17.68 billion, a PE ratio of 43.66, a PEG ratio of 3.62 and a beta of 1.30. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. On average, analysts predict that Insulet Co. will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.